LAVAL – Moderna has completed construction of its state-of-the art mRNA manufacturing facility in Laval, Quebec. The facility is expected to be ready to manufacture respiratory mRNA vaccines for Canadians in 2025, pending regulatory approvals and certifications, ensuring all vaccines manufactured meet the strictest quality, safety and performance standards. The construction of this facility marks an important milestone in Moderna’s …